Last reviewed · How we verify

NCT07499934: EMIP

Experience of UHR and PEP Individuals During Mindfulness: a Qualitative Phenomenological Study

Recruiting now NA Last updated 30 March 2026
What this trial tests

NA trial testing Qualitative interview in Clinical High Risk for Psychosis (CHR) in 20 participants. Currently enrolling.

Timeline
19 January 2026
Primary endpoint
19 January 2027
19 July 2027

Quick facts

Lead sponsorCentre Psychothérapique de Nancy
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment20
Start date19 January 2026
Primary completion19 January 2027
Estimated completion19 July 2027
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Psychothérapique de Nancy

Who can join

Adults 15 to 30, any sex, with Clinical High Risk for Psychosis (CHR). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this qualitative study is to explore and describe the lived experiences of individuals at ultra-high risk (UHR) or first episode of psychosis (FEP) who have participated in a group-based mindfulness-based intervention. Secondary objectives include identifying potential adverse effects of a group-based mindfulness-based intervention among UHR or FEP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Qualitative interview

Trials testing the same drug.

Other recruiting trials for Clinical High Risk for Psychosis (CHR)

Currently open trials in the same condition.

Other Centre Psychothérapique de Nancy trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07499934.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing